A trial (Schlumberger et al, 1995) with etoposide given as a single agent did not confirm a previous report (Hoskin and Harmer, 1987) as no tumour response was observed among 16 evaluable patients.
Combination of drugs which have been shown to be active in the treatment of other neuroendocrine tumours may provide further therapeutic options in MTC patients. Indeed, several trials carried out on limited numbers of MTC patients have shown that these drugs are active in some. With the combination of 5FU-dacarbazine, a complete response was observed in one patient (Pertusson, 1988) , and 3 partial responses were observed among 5 patients (Orlandi et al, 1994) . Two partial responses were observed among 7 patients treated with cyclophosphamide, vincristine and dacarbazine (Wu et al, 1994) . With a combination of doxorubicin and streptozocin, one partial response was obtained among 5 patients (Frame et al, 1988) , and using a combination of epirubicin, 5-FU and dacarbazine, one partial response was observed among 7 patients (Di Bartolomeo et al, 1995) . In a previous study (Schlumberger et al, 1995) , combinations of 5-FU/streptozocin and 5-FU/dacarbazine were given alternatively to 20 patients. Three partial responses and 11 stabilizations were observed.
Considering these results, the alternating combinations of doxorubicin/streptozocin and 5-FU/dacarbazine, that have already been used in gastro-entero-pancreatic neuroendocrine tumours (Moertel et al, 1994) , were given to 20 patients with progressive metastatic MTC. From October 1994 to February 1999 (Table 1) with progressive distant metastases of MTC were entered into this trial. Their mean age was 49 years (range 30-79). There were 14 males and 6 females. Among them, 16 had undergone a total thyroidectomy with bilateral cervical lymph node dissection, and 10 had received post-operatively external radiotherapy to the neck and mediastinum. Four patients were not operated on for diffuse distant metastases at presentation or locally advanced disease. None of them had previously been treated with chemotherapy. Median follow-up since the diagnosis was 4.5 years (range, 2.3-37 years).
PATIENTS AND METHODS

Patients
All patients had measurable metastatic lesions that were documented by chest radiography, neck or liver ultrasonography, and neck, chest or abdominal CT scan or magnetic resonance imaging. These lesions have progressed during the preceding 3-6 months. The tumour markers calcitonin (CT) and carcinoembryonic antigen (CEA) were measured and followed in all patients but were not accepted as the only response criteria.
Other eligibility requirements were as follows: ECOG status <2, no major ECG changes and an ejection fraction >50% as measured by an isotopic technique; leucocyte count greater than 4000 µl -1 and platelet count greater than 150 000 µl -1 , a serum creatinine of 120 µmol l -1 or less, a 24 h proteinuria <200 mg, a total bilirubin of less than or equal to 34 µmol l -1 . All patients were evaluated upon entry into the study, and after every 2 courses of chemotherapy, with clinical staging, CT and CEA measurements and morphological investigations including chest X-ray, neck and liver ultrasonography and chest or abdominal CT scan. Routine chemistry and ECG were performed before each course of chemotherapy.
The study was approved by the local Ethics Committee and an informed consent was obtained from all patients.
Treatment
The chemotherapy protocol consisted in doxorubicin 60 mg/m 2 i.v. in 5 minutes on day 1, and streptozocin 500 mg/m 2 in 4 hours perfusion, daily for 5 consecutive days. Four weeks later, 5-FU was given at 400 mg/m 2 , and dacarbazine at 200 mg/m 2 , both by intravenous injection daily for 5 consecutive days. At 8 weeks, this cycle was repeated.
Three categories of response were assessed: (1) tumour, (2) biochemical, and (3) symptomatic. The criteria used for reporting responses for measurable tumour masses were those of Miller et al (1981) : partial remission (PR) was defined as greater than or equal to 50% decrease in the sum of the products of the two largest perpendicular diameters of all tumour masses for at least 1 month; no change (NC), defined as less than 50% decrease or less than 25% increase in the size of measurable lesions; progressive disease (P) defined as greater than or equal to 25% increase in any tumour lesion or the appearance of new site. For biochemical response, PR was defined as greater than or equal to 50% decrease for at least 1 month. For symptomatic response, PR was defined as a reduction of at least 50% in both the frequency and intensity of flushing and/or diarrhoea attacks. In those patients who achieved a partial response, the period of overall duration of response was calculated from the first day of treatment to the date of first observation of progressive disease.
Toxicity was evaluated monthly and complete re-staging was performed after 2, 4 and 6 cycles of chemotherapy. Therapy was continued until tumour progression, and in cases of tumour response or stabilization for a total of 6 cycles (12 months), and as long as there was no evidence of symptomatic or general deterioration or toxicity.
RESULTS
The 20 patients entered into this trial were evaluable for toxicity and response. Each patient received an average of 4 (range 2 to 6) cycles of doxorubicin-streptozocin and 5-FU-dacarbazine.
Four of the 5 patients with invalidating symptoms before starting chemotherapy had a partial symptomatic response.
Three partial tumour responses were obtained after 3, 2 and 3 cycles of chemotherapy, and lasted 27, 28+ and 18 months, respectively. Calcitonin level decreased by 65%, 73% and 58% respectively, and CEA level was stable in one patient, was normal in one before therapy, and decreased by 60% in one.
Ten patients had a stable disease for 8-51 months (mean 23 months). Among these 10 patients, 3 had progressive marker levels, 4 had stable marker levels and 3 had a partial biological response. Seven patients had progressive disease.
Nausea and vomiting were limited by antiemetic drugs and digestive toxicity was observed in 5 patients (grade 2 in 3 and grade 3 in 2). One patient had a grade 2 stomatitis. Hepatic toxicity (grade 2) was observed in one patient, haematologic toxicity in 2 patients (grade 3 and 4), and cardiac toxicity in two patients (grade 3). There were no treatment-related deaths.
With a mean follow-up of 25 months (range, 8-60 months) since the beginning of therapy, seven deaths occurred, including one among the 3 patients who had responded to therapy, 2 among the 10 patients who achieved a stabilisation of the disease, and 4 in the 7 patients with progressive disease.
DISCUSSION
The alternating combination of doxorubicin-streptozocin, and 5-FU-dacarbazine, was used because it combines drugs that have been shown to be active in medullary thyroid carcinoma, when used separately; also, this association has been shown to be active in other neuroendocrine tumours, with an acceptable toxicity (Moertel et al, 1994) .
In 20 patients with metastatic MTC, it resulted in 3 partial responses (15%), and in 10 long-term stabilisations (50%). Considering that all patients included in the trial were affected by a rapidly progressing disease, these results confirm the potential benefits of cytotoxic chemotherapy, and are in agreement with the results obtained with the association of epirubicin, dacarbazine and 5-FU (Di Bartolomeo et al, 1995) . Nevertheless, the response rate was not improved by adding doxorubicin to the previously tested regimen of streptozocin plus 5-FU and dacarbazine, and toxicity was slightly higher (Schlumberger et al, 1995) . Therefore, we consider the previous regimen as the reference combination for metastatic MTC patients with rapidly progressing disease. The absence of synergistic effect among these cytotoxic agents can be attributed to the large size of the neoplastic masses and also to intrinsic cellular factors determining chemoresistance (Yang et al, 1991) .
Nevertheless, because of the high metastatic potential of medullary thyroid carcinoma, further studies are necessary in order to identify new therapeutic strategies with cytotoxic or cytostatic molecules that will permit the treatment of these patients at an earlier stage.
